| Primary |
| Central Nervous System Lymphoma |
13.8% |
| Product Used For Unknown Indication |
12.5% |
| Cerebral Infarction |
11.3% |
| Blood Brain Barrier Defect |
8.8% |
| Intracranial Pressure Increased |
8.8% |
| Scan With Contrast |
7.5% |
| Lung Infection |
5.0% |
| Nervous System Disorder |
5.0% |
| Lymphoma |
3.8% |
| Polyuria |
3.8% |
| Abnormal Sensation In Eye |
2.5% |
| Brain Operation |
2.5% |
| Headache |
2.5% |
| Hypertension |
2.5% |
| Hyponatraemia |
2.5% |
| Reduction Of Increased Intracranial Pressure |
2.5% |
| Intracranial Pressure Increased |
1.3% |
| Adjuvant Therapy |
1.3% |
| Blood Pressure |
1.3% |
| Bowel Preparation |
1.3% |
|
| Maculopathy |
23.4% |
| Renal Failure Acute |
12.8% |
| Anaphylactic Reaction |
6.4% |
| Rash Erythematous |
6.4% |
| Anaphylactoid Reaction |
4.3% |
| Medication Error |
4.3% |
| Metabolic Acidosis |
4.3% |
| Renal Impairment |
4.3% |
| Small Bowel Angioedema |
4.3% |
| Ventricular Tachycardia |
4.3% |
| Visual Disturbance |
4.3% |
| Wrong Drug Administered |
4.3% |
| Arrhythmia |
2.1% |
| Chills |
2.1% |
| Death |
2.1% |
| Diverticulitis |
2.1% |
| Dyspnoea |
2.1% |
| Haematuria |
2.1% |
| Hyperpyrexia |
2.1% |
| Hyperuricaemia |
2.1% |
|
| Secondary |
| Product Used For Unknown Indication |
29.7% |
| Drug Use For Unknown Indication |
25.8% |
| Agitation |
6.4% |
| Opportunistic Infection Prophylaxis |
5.3% |
| Hypertension |
3.8% |
| Antiretroviral Therapy |
3.2% |
| Prophylaxis |
2.5% |
| Anaesthesia |
2.2% |
| Non-small Cell Lung Cancer |
2.2% |
| Hiv Infection |
2.1% |
| Ill-defined Disorder |
2.1% |
| Antiviral Prophylaxis |
1.9% |
| Toxoplasmosis |
1.9% |
| Fluid Replacement |
1.8% |
| Sedation |
1.8% |
| Infection |
1.5% |
| Operative Haemorrhage |
1.5% |
| Pain |
1.5% |
| Rash |
1.5% |
| Antifungal Prophylaxis |
1.3% |
|
| Ventricular Extrasystoles |
23.3% |
| Toxic Epidermal Necrolysis |
18.3% |
| Renal Failure Acute |
8.3% |
| Blood Creatinine Increased |
5.0% |
| Hypotension |
5.0% |
| Rash Erythematous |
5.0% |
| Hypercreatininaemia |
3.3% |
| Hyponatraemia |
3.3% |
| Hypothermia |
3.3% |
| Intestinal Stenosis |
3.3% |
| Metabolic Alkalosis |
3.3% |
| Tachycardia |
3.3% |
| Transfusion-related Acute Lung Injury |
3.3% |
| Acute Pulmonary Oedema |
1.7% |
| Anaphylactoid Reaction |
1.7% |
| Angle Closure Glaucoma |
1.7% |
| Barotrauma |
1.7% |
| Cellulitis |
1.7% |
| Delirium |
1.7% |
| Drug Ineffective |
1.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
49.5% |
| Drug Use For Unknown Indication |
18.6% |
| Coronary Artery Bypass |
7.4% |
| Prophylaxis |
3.9% |
| Aortic Valve Replacement |
2.4% |
| Hypertension |
2.3% |
| Pain |
1.6% |
| Premedication |
1.6% |
| Prophylaxis Of Nausea And Vomiting |
1.4% |
| Catheterisation Cardiac |
1.3% |
| Gastric Cancer |
1.3% |
| Neuroblastoma |
1.3% |
| Mitral Valve Replacement |
1.2% |
| Nausea |
1.2% |
| Non-small Cell Lung Cancer |
0.9% |
| Constipation |
0.8% |
| Mitral Valve Repair |
0.8% |
| Fluid Replacement |
0.8% |
| Cardiopulmonary Bypass |
0.7% |
| Head And Neck Cancer |
0.7% |
|
| Injury |
12.0% |
| Pain |
10.6% |
| Unevaluable Event |
8.9% |
| Fear |
7.2% |
| Anxiety |
7.1% |
| Vomiting |
6.2% |
| Renal Failure |
6.1% |
| Anhedonia |
5.9% |
| Renal Failure Acute |
5.0% |
| Emotional Distress |
4.4% |
| Thrombocytopenia |
3.5% |
| Depression |
3.4% |
| Death |
3.2% |
| Renal Injury |
3.1% |
| Stress |
3.0% |
| Renal Impairment |
2.7% |
| White Blood Cell Count Decreased |
2.4% |
| Sepsis |
2.0% |
| Septic Shock |
1.7% |
| Toxic Epidermal Necrolysis |
1.6% |
|
| Interacting |
| Cerebral Infarction |
47.2% |
| Lung Infection |
33.3% |
| Type 2 Diabetes Mellitus |
8.3% |
| Generalised Anxiety Disorder |
5.6% |
| Pain In Extremity |
2.8% |
| Platelet Aggregation Inhibition |
2.8% |
|
| Renal Failure Acute |
50.0% |
| Abnormal Dreams |
25.0% |
| Urine Output Decreased |
25.0% |
|
